Square Pharmaceuticals Limited, one of the major pharmaceuticals companies in Bangladesh, is set to build a factory in Kenya’s Athi River, a town outside Kenya’s capital Nairobi.
Square Pharmaceuticals Kenya EPZ Ltd, a subsidiary of Square Pharmaceuticals Ltd (SPL) started construction of its manufacturing plant.
Adan Mohamed, Kenya's cabinet secretary for the ministry of industry, trade and cooperatives; Maj Gen Abul Kalam Mohammad Humayun Kabir, high commissioner of Bangladesh to Kenya, and Tapan Chowdhury, managing director of Square Pharmaceuticals, attended the ceremony.
Over the last three decades, Bangladesh has developed a strong reputation in the pharmaceutical industry, manufacturing up to 97% of the drugs used locally. Square Pharmaceuticals produces a range of drugs,
focusing on those that relieve digestive distress, such as anti-acids, digestive stimulants and anti-diarrheal medicine. The company also produces herbal products and pesticides.
SPL has been running for the last 60 years with manufacturing knowledge of all possible dosages, exporting products to 42 countries including Asia, Africa, Europe and America, the statement added.
The installation of the plant will boost Kenya’s drug manufacturing profile in East Africa. With world class manufacturing technology, quality control and state-of-the-art machinery, Square Pharmaceuticals Kenya EPZ aims to fulfill the unmet demands of medicine in Kenya, Tanzania, Rwanda, Burundi, Uganda and South Sudan.
Square Pharmaceuticals says that the establishment of the Kenya plant will facilitate skills and technology transfer. The plant will be capable of manufacturing two billion tablets and capsules and 60 million bottles of liquid formulations. Commercial production is expected to begin from the first quarter of 2020.
The products will be pre-qualified through World Health Organization and supplied throughout Africa in the long run.
It will be the benchmark for Bangladeshi industry's achievements as SPL would be the first to build its own plant abroad.